Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Declaración de posición del Grupo de la Comisión Lancet de Hipertensión con respecto a la mejora mundial de las normas de exactitud para los dispositivos de medición de la presión arterial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure

    Research output: Contribution to journalJournal articleResearchpeer-review

  • James E Sharman
  • Eoin O'Brien
  • Bruce Alpert
  • Aletta E Schutte
  • Christian Delles
  • Michael Hecht Olsen
  • Roland Asmar
  • Neil Atkins
  • Eduardo Barbosa
  • David Calhoun
  • Norm R C Campbell
  • John Chalmers
  • Ivor Benjamin
  • Garry Jennings
  • Stéphane Laurent
  • Pierre Boutouyrie
  • Patricio Lopez-Jaramillo
  • Richard J McManus
  • Anastasia S Mihailidou
  • Pedro Ordunez
  • Raj Padwal
  • Paolo Palatini
  • Gianfranco Parati
  • Neil Poulter
  • Michael K Rakotz
  • Clive Rosendorff
  • Francesca Saladini
  • Angelo Scuteri
  • Weimar Sebba Barroso
  • Myeong-Chan Cho
  • Ki-Chul Sung
  • Raymond R Townsend
  • Ji-Guang Wang
  • Tine Willum Hansen
  • Gregory Wozniak
  • George Stergiou
  • en nombre del Grupo de la Comisión Lancet de Hipertensión

View graph of relations

The Lancet Commission on Hypertension identified that a key action to address the worldwide burden of high blood pressure (BP) was to improve the quality of BP measurements by using BP devices that have been validated for accuracy. Currently, there are over 3 000 commercially available BP devices, but many do not have published data on accuracy testing according to established scientific standards. This problem is enabled through weak or absent regulations that allow clearance of devices for commercial use without formal validation. In addition, new BP technologies have emerged (e.g. cuffless sensors) for which there is no scientific consensus regarding BP measurement accuracy standards. Altogether, these issues contribute to the widespread availability of clinic and home BP devices with limited or uncertain accuracy, leading to inappropriate hypertension diagnosis, management and drug treatment on a global scale. The most significant problems relating to the accuracy of BP devices can be resolved by the regulatory requirement for mandatory independent validation of BP devices according to the universally-accepted International Organization for Standardization Standard. This is a primary recommendation for which there is an urgent international need. Other key recommendations are development of validation standards specifically for new BP technologies and online lists of accurate devices that are accessible to consumers and health professionals. Recommendations are aligned with WHO policies on medical devices and universal healthcare. Adherence to recommendations would increase the global availability of accurate BP devices and result in better diagnosis and treatment of hypertension, thus decreasing the worldwide burden from high BP.

Translated title of the contributionLancet Commission on Hypertension Group position statement on the global improvement of accuracy standards for devices that measure blood pressurePosicionamento do Grupo da Lancet Commission on Hypertension sobre a melhoria global dos padrões de acurácia para aparelhos que medem a pressão arterial
Original languageSpanish
JournalRevista Panamericana de Salud Publica/Pan American Journal of Public Health
Volume44
Pages (from-to)e21
ISSN1680-5348
DOIs
Publication statusPublished - 2020

ID: 61377336